---
title: "Pharmala Biotech 任命 Lennie Ryer 加入董事會，同時 Malik Slassi 辭去職務"
description: "Pharmala Biotech Holdings Inc. 宣佈其董事會發生變更，Dr. Malik Slassi 辭職，Lennie Ryer, CPA, CA 被任命為新董事會成員。此次更新是公司持續治理調整的一部分"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275514575.md"
published_at: "2026-02-10T21:40:08.000Z"
---

# Pharmala Biotech 任命 Lennie Ryer 加入董事會，同時 Malik Slassi 辭去職務

> Pharmala Biotech Holdings Inc. 宣佈其董事會發生變更，Dr. Malik Slassi 辭職，Lennie Ryer, CPA, CA 被任命為新董事會成員。此次更新是公司持續治理調整的一部分

Pharmala Biotech Holdings Inc. 宣佈其董事會發生變更。Dr. Malik Slassi 已辭去董事職務，Lennie Ryer, CPA, CA 被任命為新董事。免責聲明：本新聞簡報由公共技術公司（PUBT）使用生成性人工智能創建。儘管 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。Pharmala Biotech Holdings Inc. 於 2026 年 2 月 10 日通過 GlobeNewswire 發佈了用於生成本新聞簡報的原始內容（參考 ID：GNW9652217-en），並對其中包含的信息承擔全部責任。© 版權 2026 - 公共技術公司（PUBT）

### Related Stocks

- [PMCB.US - PharmaCyte Biotech](https://longbridge.com/zh-HK/quote/PMCB.US.md)
- [PBPH.US - Portfolio Bldg Blck Wld Phrm &BtchIdxETF](https://longbridge.com/zh-HK/quote/PBPH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BB Biotech AG proposes CHF 2.25 per share dividend | BB Biotech AG has proposed a dividend of CHF 2.25 per share for the 2025 financial year, an increase from CHF 1.80 per s | [Link](https://longbridge.com/zh-HK/news/273469604.md) |
| PharmaCyte Biotech CEO Joshua Silverman Acquires Common Shares | PharmaCyte Biotech CEO Joshua Silverman has acquired common shares of the company. The full filing is available through  | [Link](https://longbridge.com/zh-HK/news/271847803.md) |
| Kane Biotech Expands Commercial Activities in the United States \| KNBIF Stock News | Kane Biotech Inc. has signed non-exclusive distribution agreements for its revyve® Antimicrobial Wound Gel product line  | [Link](https://longbridge.com/zh-HK/news/276332084.md) |
| Cibc World Market Inc. Invests $1.22 Million in QXO, Inc. $QXO | Cibc World Market Inc. has invested $1.22 million in QXO, Inc. by acquiring 64,153 shares during Q3, as reported in its  | [Link](https://longbridge.com/zh-HK/news/276106337.md) |
| BB Biotech Benefits from Improved Market Environment | BB Biotech has reported a net profit of 578 million francs for 2025, significantly up from 76 million francs in 2024. Th | [Link](https://longbridge.com/zh-HK/news/276427224.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。